Skip to content

Medical information

Fresenius Medical Care is dedicated to delivering the most up-to-date, high-quality and reliable clinical and scientific information on our products to healthcare professionals and patients.

Downloads

Further statement on the withdrawal of APEX time on POL 6.2
ECMO (ExtraCorporeal Membrane Oxygenation) in Covid-19 Disease 1
Statement on investigations of CorDiax-associated adverse events 2
The Role and Benefit of Extracorporeal Blood Purification in Critically Ill COVID-19 Patients

ECMO enables gas exchange and circulation, respectively, when standard treatment fails — thus providing clinicians time to treat patients; despite a currently unclear overall benefit ECMO numbers in COVID-19 are increasing rapidly in Europe and USA

Fresenius Medical Care initiated a project in 2015 with the intent to investigate the root cause of certain hypersensitivity-like adverse events associated with dialyzers of the CorDiax product line. The project was completed in 2019 and reported to the Management Board of Fresenius Medical Care. This communication serves as a high-level summary of the findings and conclusions of the investigation.